ERBB2 and breast lobular carcinoma: Altogether 20 FFPE samples were subjected to FoundationOne®CDx testing: 10 patients with ERBB2‐amplified lobular carcinoma and 10 patients with ERBB2‐unamplified lobular carcinoma.